Predict your next investment

HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research

See what CB Insights has to offer

Stage

Acquired | Acquired

About Hema Diagnostic Systems

Hema Diagnostic Systems has designed, engineered, and manufactured a series of new rapid diagnostic tests for infectious diseases that include hepatitis B, hepatitis C, malaria, HIV, tuberculosis, syphilis and dengue.

Hema Diagnostic Systems Headquarter Location

10102 USA Today Way

Miramar, Florida, 33025,

United States

954-919-5123

Latest Hema Diagnostic Systems News

Generex Announces Investor Conference Call; Management to Provide Update on Initiatives & Strategic Plans

Dec 18, 2017

The purpose of the conference call will be to provide investors with an update on the Company’s initiatives and strategic plans, including its capital reorganization, its controlling interest in Hema Diagnostic Systems, LLC ( www.hemadiagnosticsystems.com ), the recently announced initiatives of Antigen Express, Inc. ( www.antigenexpress.com ), the Company’s wholly-owned immuno-therapeutics subsidiary, with Merck Sharp & Dohme B.V. and Shenzhen BioScien Pharmaceuticals Co. Ltd., and the Company’s buccal drug delivery platform technologies. Joseph Moscato, the Generex President & Chief Executive Officer, stated: “2017 has been a very busy, productive, and revitalizing year for Generex. I am looking forward to reviewing this past year with my fellow stockholders and providing a glimpse of what the future holds for our Company.” Cautionary Note Regarding Forward-Looking Statements This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act. View source version on businesswire.com: http://www.businesswire.com/news/home/20171218005296/en/ Generex Biotechnology Corporation

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.